PFS-话题@MedSci

#PFS#

70篇内容 | 2863人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1448653, encodeId=8c4d14486536e, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=JCO：中位PFS 25.8月！GA101+苯达莫司汀方案可显著改善难治性惰性NHL患者生存, objectType=article, longId=147021, objectId=15b014e02131, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15b014e02131, replyNumber=0, likeNumber=83, createdTime=2018-08-21, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15b014e02131, moduleTitle=JCO：中位PFS 25.8月！GA101+苯达莫司汀方案可显著改善难治性惰性NHL患者生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15b014e02131)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448652, encodeId=f2d2144865234, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=LANCET INFEC DIS: Pfs25H-EPA/Alhydrogel传播阻断疫苗的安全性和免疫原性, objectType=article, longId=146610, objectId=622f146610c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=622f146610c5, replyNumber=0, likeNumber=63, createdTime=2018-08-16, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=622f146610c5, moduleTitle=LANCET INFEC DIS: Pfs25H-EPA/Alhydrogel传播阻断疫苗的安全性和免疫原性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=622f146610c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448651, encodeId=f64c144865188, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=Takeda的Alunbrig在ALK阳性NSCLC的PFS击败了辉瑞公司的Xalkori, objectType=article, longId=145287, objectId=5cfb14528e84, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cfb14528e84, replyNumber=0, likeNumber=39, createdTime=2018-07-28, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cfb14528e84, moduleTitle=Takeda的Alunbrig在ALK阳性NSCLC的PFS击败了辉瑞公司的Xalkori, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cfb14528e84)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448650, encodeId=c94b144865094, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=Opdivo / Yervoy联用在肺癌中的PFS上优于单一化疗, objectType=article, longId=129142, objectId=752c12914223, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=752c12914223, replyNumber=0, likeNumber=77, createdTime=2018-02-08, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=752c12914223, moduleTitle=Opdivo / Yervoy联用在肺癌中的PFS上优于单一化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=752c12914223)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448649, encodeId=ca921448649a5, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=罗氏肺癌联合化疗延长PFS, objectType=article, longId=122815, objectId=ae5b12281576, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae5b12281576, replyNumber=0, likeNumber=77, createdTime=2017-12-10, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae5b12281576, moduleTitle=罗氏肺癌联合化疗延长PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae5b12281576)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448648, encodeId=50df1448648a8, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=【ESMO Asia】FLAURA研究：奥希替尼显著延长PFS及ORR, objectType=article, longId=120734, objectId=3f0d120e34d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f0d120e34d1, replyNumber=0, likeNumber=70, createdTime=2017-11-21, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f0d120e34d1, moduleTitle=【ESMO Asia】FLAURA研究：奥希替尼显著延长PFS及ORR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f0d120e34d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448647, encodeId=948f144864ee9, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=【ESMO Asia】PACIFIC研究：Durvalumab显著延长局部晚期NSCLC的PFS, objectType=article, longId=120733, objectId=d89c120e33b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d89c120e33b7, replyNumber=0, likeNumber=66, createdTime=2017-11-21, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d89c120e33b7, moduleTitle=【ESMO Asia】PACIFIC研究：Durvalumab显著延长局部晚期NSCLC的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d89c120e33b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448646, encodeId=c54a144864688, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=JAMA Oncol：NSCLC寡转移∣局部放疗较维持治疗延长近3倍PFS, objectType=article, longId=115576, objectId=20ad1155e62a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20ad1155e62a, replyNumber=0, likeNumber=62, createdTime=2017-10-11, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20ad1155e62a, moduleTitle=JAMA Oncol：NSCLC寡转移∣局部放疗较维持治疗延长近3倍PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20ad1155e62a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448645, encodeId=a286144864539, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=JAMA Oncology：【ASTRO 2017】LBA-3：立体定向消融放疗（SAbR）可提高NSCLC的PFS达三倍！, objectType=article, longId=115242, objectId=7c2011524243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c2011524243, replyNumber=0, likeNumber=36, createdTime=2017-10-06, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c2011524243, moduleTitle=JAMA Oncology：【ASTRO 2017】LBA-3：立体定向消融放疗（SAbR）可提高NSCLC的PFS达三倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c2011524243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448644, encodeId=f8d81448644d9, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=Ann Oncol:β阻滞剂或可使三阴性乳腺癌患者的PFS增加2倍以上？, objectType=article, longId=108711, objectId=2c37108e1114, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c37108e1114, replyNumber=0, likeNumber=131, createdTime=2017-08-15, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c37108e1114, moduleTitle=Ann Oncol:β阻滞剂或可使三阴性乳腺癌患者的PFS增加2倍以上？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c37108e1114)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448643, encodeId=f2cb14486432a, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS, objectType=article, longId=79864, objectId=5769e986481, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5769e986481, replyNumber=0, likeNumber=73, createdTime=2016-10-13, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5769e986481, moduleTitle=ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5769e986481)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448642, encodeId=2ff614486424e, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ESMO 2016：卡铂+培美曲塞+派姆单抗，可改善NSCLC患者的PFS, objectType=article, longId=79863, objectId=3fa9e98630a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fa9e98630a, replyNumber=0, likeNumber=71, createdTime=2016-10-13, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fa9e98630a, moduleTitle=ESMO 2016：卡铂+培美曲塞+派姆单抗，可改善NSCLC患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fa9e98630a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448641, encodeId=04a31448641aa, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）, objectType=article, longId=79630, objectId=1d17e9630e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d17e9630e6, replyNumber=0, likeNumber=31, createdTime=2016-10-11, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d17e9630e6, moduleTitle=ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d17e9630e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448640, encodeId=c705144864035, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ESMO 2016：Niraparib可延长复发性卵巢癌患者的PFS, objectType=article, longId=79625, objectId=03fde96257d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03fde96257d, replyNumber=0, likeNumber=52, createdTime=2016-10-11, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03fde96257d, moduleTitle=ESMO 2016：Niraparib可延长复发性卵巢癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03fde96257d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448639, encodeId=c0471448639b8, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ELCC 2016：Tagrisso一线治疗EGFR T790M突变NSCLC患者，PFS长达19.3个月, objectType=article, longId=66570, objectId=3bc2665e07d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bc2665e07d, replyNumber=0, likeNumber=95, createdTime=2016-04-17, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bc2665e07d, moduleTitle=ELCC 2016：Tagrisso一线治疗EGFR T790M突变NSCLC患者，PFS长达19.3个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bc2665e07d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448638, encodeId=6b4514486381e, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ASCO 2015：Palbociclib 改善乳腺癌PFS（PALOMA-3试验）, objectType=article, longId=51403, objectId=701c51403d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=701c51403d1, replyNumber=0, likeNumber=72, createdTime=2015-05-31, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=701c51403d1, moduleTitle=ASCO 2015：Palbociclib 改善乳腺癌PFS（PALOMA-3试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=701c51403d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448637, encodeId=53da144863eed, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=JCO：舒尼替尼维持治疗可改善小细胞肺癌无进展生存期PFS（II期研究）, objectType=article, longId=50196, objectId=b7285019648, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7285019648, replyNumber=0, likeNumber=56, createdTime=2015-05-06, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7285019648, moduleTitle=JCO：舒尼替尼维持治疗可改善小细胞肺癌无进展生存期PFS（II期研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7285019648)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448636, encodeId=7e1f1448636a4, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=Clin Cancer Res：OS和PFS在胃肠间质瘤之中的联系（meta分析）, objectType=article, longId=46304, objectId=d734463049f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d734463049f, replyNumber=0, likeNumber=82, createdTime=2015-01-30, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d734463049f, moduleTitle=Clin Cancer Res：OS和PFS在胃肠间质瘤之中的联系（meta分析）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d734463049f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448635, encodeId=fd8c144863523, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ASCO GI 2015：徐瑞华：Famitinib可改善晚期结直肠癌患者PFS, objectType=article, longId=45867, objectId=ab984586ebc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab984586ebc, replyNumber=0, likeNumber=64, createdTime=2015-01-22, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab984586ebc, moduleTitle=ASCO GI 2015：徐瑞华：Famitinib可改善晚期结直肠癌患者PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab984586ebc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448634, encodeId=801c1448634b0, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=Lancet Oncol：贝伐珠单抗+二线化疗能改善HER2阴性乳腺癌PFS (TANIA研究), objectType=article, longId=41274, objectId=a319412e4e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a319412e4e0, replyNumber=0, likeNumber=82, createdTime=2014-10-16, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a319412e4e0, moduleTitle=Lancet Oncol：贝伐珠单抗+二线化疗能改善HER2阴性乳腺癌PFS (TANIA研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a319412e4e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PFS

2020-05-29

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

JCO：中位PFS 25.8月！GA101+苯达莫司汀方案可显著改善难治性惰性NHL患者生存

2018-08-21

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

LANCET INFEC DIS: Pfs25H-EPA/Alhydrogel传播阻断疫苗的安全性和免疫原性

2018-08-16

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

Takeda的Alunbrig在ALK阳性NSCLC的PFS击败了辉瑞公司的Xalkori

2018-07-28

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

Opdivo / Yervoy联用在肺癌中的PFS上优于单一化疗

2018-02-08

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

罗氏肺癌联合化疗延长PFS

2017-12-10

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

【ESMO Asia】FLAURA研究：奥希替尼显著延长PFS及ORR

2017-11-21

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

【ESMO Asia】PACIFIC研究：Durvalumab显著延长局部晚期NSCLC的PFS

2017-11-21

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

JAMA Oncol：NSCLC寡转移∣局部放疗较维持治疗延长近3倍PFS

2017-10-11

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

JAMA Oncology：【ASTRO 2017】LBA-3：立体定向消融放疗（SAbR）可提高NSCLC的PFS达三倍！

2017-10-06

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

Ann Oncol:β阻滞剂或可使三阴性乳腺癌患者的PFS增加2倍以上？

2017-08-15

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ESMO 2016：Ceritinib可延长ALK阳性非小细胞肺癌患者的PFS

2016-10-13

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ESMO 2016：卡铂+培美曲塞+派姆单抗，可改善NSCLC患者的PFS

2016-10-13

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ESMO 2016：来曲唑+Ribociclib可延长激素受体阳性、HER-2阴性晚期乳腺癌患者的PFS（MONALEESA-2试验）

2016-10-11

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ESMO 2016：Niraparib可延长复发性卵巢癌患者的PFS

2016-10-11

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ELCC 2016：Tagrisso一线治疗EGFR T790M突变NSCLC患者，PFS长达19.3个月

2016-04-17

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ASCO 2015：Palbociclib 改善乳腺癌PFS（PALOMA-3试验）

2015-05-31

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

JCO：舒尼替尼维持治疗可改善小细胞肺癌无进展生存期PFS（II期研究）

2015-05-06

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

Clin Cancer Res：OS和PFS在胃肠间质瘤之中的联系（meta分析）

2015-01-30

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ASCO GI 2015：徐瑞华：Famitinib可改善晚期结直肠癌患者PFS

2015-01-22

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

Lancet Oncol：贝伐珠单抗+二线化疗能改善HER2阴性乳腺癌PFS (TANIA研究)

2014-10-16

科室
- - 订阅+
  - 更多科室
工具
服务